Piperlongumine and its derivatives against cancer: A recent update and future prospective
- PMID: 38593312
- DOI: 10.1002/ardp.202300768
Piperlongumine and its derivatives against cancer: A recent update and future prospective
Abstract
Piperlongumine, or piplartine (PL), is a bioactive alkaloid isolated from Piper longum L. and a potent phytoconstituent in Indian Ayurveda and traditional Chinese medicine with a lot of therapeutic benefits. Apart from all of its biological activities, it demonstrates multimodal anticancer activity by targeting various cancer-associated pathways and being less toxic to normal cells. According to their structure-activity relationship (SAR), the trimethylphenyl ring (cinnamoyl core) and 5,6-dihydropyridin-2-(1H)-one (piperdine core) are responsible for the potent anticancer activity. However, it has poor intrinsic properties (low aqueous solubility, poor bioavailability, etc.). As a result, pharmaceutical researchers have been trying to optimise or modify the structure of PL to improve the drug-likeness profiles. The present review selected 26 eligible research articles on PL derivatives published between 2012 and 2023, followed by the preferred reporting items for systematic reviews and meta-analyses (PRISMA) format. We have thoroughly summarised the anticancer potency, mode of action, SAR and drug chemistry of the proposed PL-derivatives against different cancer cells. Overall, SAR analyses with respect to anticancer potency and drug-ability revealed that substitution of methoxy to hydroxyl, attachment of ligustrazine and 4-hydroxycoumarin heterocyclic rings in place of phenyl rings, and attachment of heterocyclic rings like indole at the C7-C8 olefin position in native PL can help to improve anticancer activity, aqueous solubility, cell permeability, and bioavailability, making them potential leads. Hopefully, the large-scale collection and critical drug-chemistry analyses will be helpful to pharmaceutical and academic researchers in developing potential, less-toxic and cost-effective PL-derivatives that can be used against different cancers.
Keywords: cancer; phytochemicals; piperlongumine and its derivatives; solubility and bioavailability profiles; structure–activity relationship.
© 2024 Deutsche Pharmazeutische Gesellschaft.
Similar articles
-
Piperlongumine (piplartine) as a lead compound for anticancer agents - Synthesis and properties of analogues: A mini-review.Eur J Med Chem. 2018 Aug 5;156:13-20. doi: 10.1016/j.ejmech.2018.06.057. Epub 2018 Jun 25. Eur J Med Chem. 2018. PMID: 30006159 Review.
-
Piperlongumine: the amazing amide alkaloid from Piper in the treatment of breast cancer.Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):2637-2650. doi: 10.1007/s00210-023-02673-5. Epub 2023 Nov 13. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37955690 Review.
-
Overview of piperlongumine analogues and their therapeutic potential.Eur J Med Chem. 2021 Aug 5;220:113471. doi: 10.1016/j.ejmech.2021.113471. Epub 2021 Apr 21. Eur J Med Chem. 2021. PMID: 33930801 Review.
-
[Research progress in anti-tumor activity and nano-drug delivery system of piperlongumine].Zhongguo Zhong Yao Za Zhi. 2024 Apr;49(8):2117-2127. doi: 10.19540/j.cnki.cjcmm.20231206.301. Zhongguo Zhong Yao Za Zhi. 2024. PMID: 38812227 Review. Chinese.
-
Novel non-trimethoxylphenyl piperlongumine derivatives selectively kill cancer cells.Bioorg Med Chem Lett. 2017 Jun 1;27(11):2308-2312. doi: 10.1016/j.bmcl.2017.04.035. Epub 2017 Apr 13. Bioorg Med Chem Lett. 2017. PMID: 28434764
References
REFERENCES
-
- S. Sidney, C. Lee, J. Liu, S. S. Khan, D. M. Lloyd‐Jones, J. S. Rana, JAMA Netw. Open 2022, 5, e223872.
-
- S. C. Shah, V. Kayamba, R. M. Peek Jr., D. Heimburger, J. Glob. Oncol. 2019, 5, 1.
-
- H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, CA Cancer J. Clin. 2021, 71, 209.
-
- WHO‐Cancer Today Report‐2020. https://gco.iarc.fr/today/home
-
- O. Abdel‐Rahman, J. Comp. Eff. Res. 2021, 10, 969.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous